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Myers et al. Respond
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We are in complete agreement with the 
statement by Becker et al. that “having con-
fidence in scientific procedures and data is 
the sine qua non for determining the safety 
of chemicals and chemical products.” Our 
aim in writing the commentary (Myers et al. 
2009) was not to challenge the original 
intent of Good Laboratory Practices (GLP) 
requirements, which was to establish stan-
dards of record keeping in contract labora-
tory research so as to reduce the likelihood 
of fraud. Our goal instead was to show—
through an analysis of the application of 
GLP data on bisphenol A (BPA) in regu-
latory proceedings—that GLP by itself is 
insufficient to guarantee valid and reliable 
science. Becker et al. appear to have missed 
the point of our commentary entirely. 
In the case of BPA, three GLP studies 
have been offered by industry-sponsored 
laboratories as proof of the chemical’s safety 
(Cagen et al. 1999; Tyl et al. 2002, 2008). 
Each has errors in study design and/or data 
interpretation that are sufficiently serious as 
to invalidate the conclusions of these studies 
(Myers et al. 2009). Nevertheless, because the 
studies were conducted using GLP guidelines, 
they were judged by regulators as being more 
reliable than the many National Institutes 
of Health (NIH)-funded and peer-reviewed 
studies that have reported adverse effects 
(Richter et al. 2007; vom Saal et al. 2007). 
As our commentary (Myers et al. 2009)
clearly establishes, GLP did not guaran-
tee the scientific validity of these three stud-
ies. Because previous analyses had identified 
serious flaws in the first two of those GLP 
studies, we focused critical attention on the 
most recent (Tyl et al. 2008), which both the 
European Food Safety Authority (EFSA 2006) 
and the U.S. Food and Drug Administration 
(FDA) had identified as key in their BPA risk 
assessments (FDA 2008). We found three 
main flaws: a) the animals were inexplicably 
insensitive to estrogen; b) the assays were out-
dated and insensitive compared with methods 
used in NIH-funded research showing adverse 
effects; and c) validity of the findings was chal-
lenged. For example, the prostate weights of 
control animals reported by Tyl et al. (2008) 
were > 70% larger (mean, > 72 mg) than those 
reported by numerous laboratories, includ-
ing a previously published study using CD-1 
mice [conducted at RTI, where the study by 
Tyl et al. (2008) was conducted] that reported 
mean prostate weights of 46 mg in CD-1 
males that were examined at a similar age 
(Heindel et al. 1995).
Since we published our commentary 
(Myers et al. 2009), a possible contributor 
to both the estrogen insensitivity and the 
enlarged control prostates has been suggested: 
Approximately 3 years before the experiments 
that formed the basis of the study by Tyl et al. 
(2008), there was a polycarbonate fire that 
released BPA into the RTI laboratory where 
the research was conducted (Kissinger and 
Rust 2009). An investigation revealed that 
animals in the laboratory were exposed to low 
doses of BPA that government-funded sci-
ence (Richter et al. 2007) indicates could affect 
research animals.
Additional uncertainties about Tyl et al.’s 
study (Tyl et al. 2008) have now been iden-
tified by the lead author. Whereas the pub-
lished paper reports that the animals were 
examined at approximately 14 weeks of age, 
Tyl testified at an FDA hearing in September 
2008 that they were 6 months of age, and 
then at a German Environmental Protection 
Agency hearing in March 2009 that they were 
5 months of age (Kissinger and Rust 2009). 
#ere she confirmed that the information in 
the original article was inaccurate. Because an 
animal’s physiology changes as it ages, these 
contradictory statements are problematic for 
all reported outcomes; even at 5–6 months 
of age, normal, healthy CD-1 male mice 
would not have the grossly enlarged prostates 
reported by Tyl et al. (2008).
#e use of flawed science, however, is not 
the only concern. #e type of multi generation 
testing approach used in these studies is, quite 
simply, insufficient for the testing of endo-
crine-disrupting chemicals. #is is not a new 
concept. #e need for more specific tests for 
endocrine-active compounds led in 1998 to 
the establishment at the U.S. Environmental 
Protection Agency (U.S. EPA) of the 
Endocrine Disruptor Screening Program, 
mandated by Congress (U.S. EPA 1998). 
After virtually no progress for over a decade, 
in 2009 the U.S. EPA finally announced a set 
of testing procedures that will be examined. 
The proposed “new” methodology, heavily 
dependent upon traditional toxicologic meth-
ods used in multi generational GLP studies, is 
still woefully inadequate (Colborn 2009). 
#e letter by Becker et al. provides a strik-
ing example of the reluctance of industry lob-
byists to hear this message. In the eyes of the 
36 scientific colleagues who co authored our 
commentary (Myers et al. 2009), the BPA 
studies that Becker et al. attempt to defend 
are so seriously flawed as to be indefensible. 
Rather than continue to defend a dead issue, 
we encourage industry representatives to come 
into the 21st century and help us devise new 
paradigms for testing endocrine-disrupting 
chemicals that will safeguard human health. 
The authors’ freedom to design, conduct, 
interpret, and publish this letter was not nor is 
compromised by any controlling sponsor as a con-
dition of review and publication.
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Electromagnetic Fields and the 
Precautionary Principle
doi:10.1289/ehp.0901111
Since Galileo, debates in science are sup-
ported by logical reasoning and reference to 
statements of fact and not by reference to 
“authorities.” Consequently, litera ture serves 
or should serve two purposes: to give credit 
to thoughts expressed earlier by others, and 
to refer to statements of facts.
#e article by Dolan and Rowley (2009)— 
employees of the mobile telephone indus-
try—is an example of a compilation of points 
of views expressed by authorities. No num-
ber of references to authoritative statements 
can replace scientific discourse. #e article 
can be summarized as follows: #ere is no 
convincing evidence of harm from exposure 
to microwaves below levels recommended 
by the International Commission on Non-
Ionizing Radiation Protection (ICNIRP) 
(1998); therefore, there is no harm, and 
hence application of the precautionary prin-
ciple is not indicated. 
Indeed, the precautionary principle is not 
intended as a response to unfounded fears 
of the public or to aim at zero risk, but as a 
risk management strategy in case of scientific 
uncertainty about the existence or magni-
tude of a risk. Apparently Dolan and Rowley 
(2009) are not aware that their subjective rea-
soning does not differ from the unfounded 
fears of the public and can be summarized as 
“unfounded reassurance of no harm.”
In principle, ethical considerations, value 
judgments, and consensus play an important 
role when giving guidance to public health 
policy. This is because “it is impossible to 
derive . . . a proposal for a policy from a sen-
tence stating a fact” (Popper 1945). Use of 
subjective terms such as “sufficient evidence” 
(let alone “convincing evidence”— convincing 
for whom?) or “adverse effect” is unavoidable. 
Referring to the World Health Organization 
(WHO 2000), Dolan and Rowley (2009) 
stated: “#e corresponding advice to govern-
ments is to adopt science based guidelines and 
not to undermine confidence by incorporat-
ing additional arbitrary safety factors.” The 
expression “science-based guidelines,” if taken 
literally, is a contradiction in terms. Although 
public health guidelines should be based on a 
thorough risk assessment, neither the assess-
ment itself nor the reasoning that is applied 
to derive a guideline can be scientific. No sci-
entific evidence can define a margin of safety; 
no scientific evidence can replace the value 
judgment of which evidence to rely on, which 
evidence to dismiss, and so forth. Safety fac-
tors are always—at least to certain degree—
arbitrary. For example, we very rarely have 
scientific evidence about the distribution of 
sensitivity to a toxic agent in the population; 
therefore, we apply arbitrary factors for taking 
inter individual differences into account. What 
is important, and nearly always neglected in 
the area of electromagnetic fields (EMF), is to 
clearly state where value judgments and arbi-
trary decisions entered the argument and the 
derivation of guidelines. 
The international standards for EMF 
(ICNIRP 1998; IEEE 2006) are based on 
immediate effects of exposure, such as excita-
tion of nerve or muscle cells for low-frequency 
fields and increase of body tempera ture for 
high-frequency fields, not because there are 
no other effects, even at levels far below the 
guideline levels derived from these acute 
effects, but because the panels came to the 
consensus that these other effects cannot (yet) 
form the basis for the derivation of guidelines. 
For example, the International Agency for 
Research on Cancer (IARC 2002) classified 
power frequency magnetic fields as a possible 
human carcino gen. In that case, the subjec-
tivity of the assessment is fully trans parent: 
#e basic rules of IARC were violated, as the 
panel questioned whether epidemiologic evi-
dence can be causally interpreted in spite of 
evidence that neither bias nor confounding 
accounts for the increased childhood leuke-
mia risk. #e exposure level for which there is 
evidence of an increased childhood leukemia 
risk is far below the international standards, 
but the panels setting the standard did not 
use this evidence as a basis for the deriva-
tion of a guideline level for power frequency 
fields. #ere are surely many arguments for 
this decision. However, none are scientific. 
#is is not meant as a reproach, because we 
recog nize the fact that guidelines cannot be 
derived from scientific statements alone. 
It would be much more appropriate if 
Dolan and Rowley expressly stated that they 
are completely satis fied with the interna-
tional standards and that the industry does 
not want to be bothered by allusions to 
precaution.
